Ulrik Niels Lassen

Ulrik Niels Lassen

Clinical Professor

Member of:

  • Clinical Oncology


  1. 2020
  2. Published

    Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours

    Bono, P., Massard, C., Peltola, K. J., Azaro, A., Italiano, A., Kristeleit, R. S., Curigliano, G., Lassen, Ulrik Niels, Arkenau, H. T., Hakulinen, P., Garratt, C., Ikonen, T., Mustonen, M. V. J. & Rodon, J. A., 2020, In: ESMO Open. 5, 6, 11 p., e001081.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma

    Even, C., Lassen, Ulrik Niels, Merchan, J., Le Tourneau, C., Soria, J. C., Ferte, C., Ricci, F., Diener, J. T., Yuen, E., Smith, C., Oakley, G. J., Benhadji, K. A. & Massard, C., Apr 2020, In: Investigational New Drugs. 38, 2, p. 402-409

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Distress and perceived information among patients in phase I trials and their relatives: A prospective study

    Gad, K. T., Dalton, Susanne Oksbjerg, Envold, P. B., Duun-henriksen, A. K., Lassen, Ulrik Niels, Mau-sørensen, M., Rohrberg, K. S., Spanggaard, I., Von Heymann, A., Høeg, B. L. & Johansen, Christoffer, 1 Sep 2020, In: Annals of Oncology. 31, p. S497 1 p., 591P .

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  5. Published

    Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin

    Hassan, R., Alewine, C., Mian, I., Spreafico, A., Siu, L. L., Gomez-Roca, C., Delord, J. P., Italiano, A., Lassen, Ulrik Niels, Soria, J. C., Bahleda, R., Thomas, A., Steinberg, S. M., Peer, C. J., Figg, W. D., Niederfellner, G., Méresse Naegelen, V. & Pastan, I., 2020, In: Cancer. 126, 22, p. 4936-4947 12 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

    Hong, D. S., Concin, N., Vergote, I., de Bono, J. S., Slomovitz, B. M., Drew, Y., Arkenau, H-T., Machiels, J-P., Spicer, J. F., Jones, R., Forster, M. D., Cornez, N., Gennigens, C., Johnson, M. L., Thistlethwaite, F. C., Rangwala, R. A., Ghatta, S., Windfeld, K., Harris, J. R., Lassen, U. N. & 1 others, Coleman, R. L., 15 Mar 2020, In: Clinical Cancer Research. 26, 6, p. 1220-1228 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    Larotrectinib versus prior therapies in tropomyosin receptor kinase fusion cancer: An intra-patient comparative analysis

    Italiano, A., Nanda, S., Briggs, A., Garcia-Foncillas, J., Lassen, Ulrik Niels, Vassal, G., Kummar, S., van Tilburg, C. M., Hong, D. S., Laetsch, T. W., Keating, K., Reeves, J. A., Fellous, M., Childs, B. H., Drilon, A. & Hyman, D. M., 2020, In: Cancers. 12, 11, p. 1-10 10 p., 3246.

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    Entrectinib for ROS1 fusion-positive NSCLC and NTRK fusion-positive solid tumours

    Lassen, Ulrik Niels, 2020, In: Lancet Oncology. 21, 2, p. 193-194

    Research output: Contribution to journalComment/debateResearch

  9. Published

    Total burden of disease in cancer patients at diagnosis—a Danish nationwide study of multimorbidity and redeemed medication

    Loeppenthin, K., Dalton, Susanne Oksbjerg, Johansen, Christoffer, Andersen, E., Christensen, Mikkel Bring, Pappot, Helle, Petersen, L. N., Thisted, L. B., Frølich, A., Mortensen, C. E., Lassen, Ulrik Niels, Ørsted, J. & Bidstrup, P. E., 15 Sep 2020, In: British Journal of Cancer. 123, 6, p. 1033-1040 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility – a prospective, translational study

    Nørøxe, D. S., Yde, C. W., Østrup, O., Michaelsen, Signe Regner, Schmidt, A. Y., Kinalis, S., Torp, M. H., Skjøth‐Rasmussen, J., Brennum, J., Hamerlik, P., Poulsen, H. S., Nielsen, Finn Cilius & Lassen, Ulrik Niels, 2020, In: Molecular Oncology.

    Research output: Contribution to journalJournal articleResearchpeer-review

  11. Published

    Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays

    Pfarr, N., Kirchner, M., Lehmann, U., Leichsenring, J., Merkelbach-Bruse, S., Glade, J., Hummel, M., Stögbauer, F., Lehmann, A., Trautmann, M., Kumbrink, J., Jung, A., Dietmaier, W., Endris, V., Kazdal, D., Evert, M., Horst, D., Kreipe, H., Kirchner, T., Wardelmann, E. & 6 others, Lassen, Ulrik Niels, Büttner, R., Weichert, W., Dietel, M., Schirmacher, P. & Stenzinger, A., 2020, In: Genes Chromosomes and Cancer. 59, 3, p. 178-188 11 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

Previous 1 2 3 4 5 6 7 8 ...16 Next

ID: 4952653